Sep 14 2008
BioServe has announced a more affordable pricing plan for its vast bank of DNA with comprehensive, de-identified, covariate data that includes age, gender, diet, body mass index (BMI), and race. In addition, each sample has data on the complete diagnostic and treatment history of the donor.
BioServe's DNA represents a wide range of disease states including cancers (breast, prostate, lung, colon, others), diabetes, heart disease, hypertension, arthritis, obesity, as well as some rarer diseases. The repository also includes over 14,000 control subjects that are free of major illnesses. DNA is available in quantities from a few nanograms to hundreds of micrograms per subject to suit customer needs. Customized DNA panels and case-control studies can be designed based upon the investigators' needs, taking into consideration the specific data points available for each individual DNA sample. Another useful function of these DNAs is for investigators to utilize them as second group of samples to validate data generated from their studies.
"We are making high-quality DNA available at price points that are affordable to any research laboratory during these tough budgetary times," stated Kevin Krenitsky MD, Chief Executive Officer of BioServe. "This will result in many more investigators who will be able to perform their research using very well annotated DNA samples. Experiments with these DNAs can be executed both in the investigators' own lab, and/or at BioServe with a large variety of genomic platforms that are currently utilized. We also welcome collaborations that can make access even more affordable," said Dr. Krenitsky.
BioServe's DNA is obtained from human subjects that provided informed consent with strict IRB and HIPAA compliance. BioServe has obtained informed consent, detailed questionnaire data and DNA from over 120,000 subjects.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy